Top

Cellular Oncology

Published in:

01-02-2019 | Original Paper

CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer

Authors: Asim Pervaiz, Michael Zepp, Saqib Mahmood, Doaa Mohamed Ali, Martin R. Berger, Hassan Adwan

Published in: Cellular Oncology | Issue 1/2019

Abstract

Purpose

Bone metastasis is observed in up to 70% of breast cancer patients. The currently available treatment options are palliative in nature. Chemokine receptor 5 (CCR5) has gained attention as therapeutic target in various malignancies. Here, we investigated the effects of targeting CCR5 by its antagonist maraviroc in metastatic breast cancer cells.

Methods

In response to maraviroc exposure, cytotoxicity was assessed using an MTT proliferation assay, whereas the effects on colony formation and migration were assessed using colony formation, transwell chamber migration and scratch wound healing assays, respectively. Apoptosis-related activities were investigated using nuclear staining, annexin-V FITC staining and Western blotting. Cell cycle changes were analysed using flow cytometry and qRT-PCR for cell cycle relevant genes. A nude rat model for breast cancer bone metastasis was used to evaluate the in vivo efficacy of CCR5 targeting by maraviroc. Circulatory levels of the three cognate ligands for CCR5 (CCL3, CCL4, CCL5) were analysed in sera of breast cancer patients using ELISA.

Results

We found that blockade of CCR5 attenuated the proliferation, colony formation and migration of metastatic breast cancer cells, and induced apoptosis and arrest in the G1 phase of the cell cycle. Expression profiling highlighted the involvement of cell cycle related signalling cascades. We also found that treatment with maraviroc significantly inhibited bone metastasis in nude rats implanted with MDA-MB-231 breast cancer cells. Finally, we found that the circulatory levels of three cognate ligands for the CCR5 receptor varied between breast cancer patients and healthy controls.

Conclusion

Our findings indicate that targeting CCR5 may be an effective strategy to combat breast cancer bone metastasis.

Available only for authorised users

L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012. CA Cancer J Clin 65, 87–108 (2015). https://doi.org/10.3322/caac.21262 CrossRefPubMed

C. DeSantis, R. Siegel, P. Bandi, A. Jemal, Breast cancer statistics, 2011. CA Cancer J Clin 61, 409–418 (2011). https://doi.org/10.3322/caac.20134 CrossRefPubMed

M. Yousefi, R. Nosrati, A. Salmaninejad, S. Dehghani, A. Shahryari, A. Saberi, Organ-specific metastasis of breast cancer: Molecular and cellular mechanisms underlying lung metastasis. Cell Oncol 41, 123–140 (2018). https://doi.org/10.1007/s13402-018-0376-6 CrossRef

C. Fontanella, V. Fanotto, K. Rihawi, G. Aprile, F. Puglisi, Skeletal metastases from breast cancer: Pathogenesis of bone tropism and treatment strategy. Clin Exp Metastasis 32, 819–833 (2015). https://doi.org/10.1007/s10585-015-9743-0 CrossRefPubMed

H. Kennecke, R. Yerushalmi, R. Woods, M.C. Cheang, D. Voduc, C.H. Speers, T.O. Nielsen, K. Gelmon, Metastatic behavior of breast cancer subtypes. J Clin Oncol 28, 3271–3277 (2010). https://doi.org/10.1200/JCO.2009.25.9820 CrossRefPubMed

L. Gerratana, V. Fanotto, M. Bonotto, S. Bolzonello, A.M. Minisini, G. Fasola, F. Puglisi, Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis 32, 125–133 (2015). https://doi.org/10.1007/s10585-015-9697-2 CrossRefPubMed

G.R. Mundy, Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2, 584–593 (2002). https://doi.org/10.1038/nrc867 CrossRefPubMed

L.A. Liotta, E.C. Kohn, The microenvironment of the tumour-host interface. Nature 411, 375–379 (2001). https://doi.org/10.1038/35077241 CrossRefPubMed

P. Samadi, S. Saki, F.K. Dermani, M. Pourjafar, M. Saidijam, Emerging ways to treat breast cancer: Will promises be met? Cell Oncol (2018). https://doi.org/10.1007/s13402-018-0409-1

10.

M. Stanisic, S.P. Lyngstadaas, A.H. Pripp, A.O. Aasen, K.F. Lindegaard, J. Ivanovic, E. Ilstad, A. Konglund, T. Sandell, O. Ellingsen, T. Saehle, Chemokines as markers of local inflammation and angiogenesis in patients with chronic subdural hematoma: A prospective study. Acta Neurochir 154, 113–120; discussion 120 (2012). https://doi.org/10.1007/s00701-011-1203-2

11.

F.R. Balkwill, The chemokine system and cancer. J Pathol 226, 148–157 (2012). https://doi.org/10.1002/path.3029 CrossRefPubMed

12.

F. Sallusto, M. Baggiolini, Chemokines and leukocyte traffic. Nat Immunol 9, 949–952 (2008). https://doi.org/10.1038/ni.f.214 CrossRefPubMed

13.

A. Mantovani, R. Bonecchi, M. Locati, Tuning inflammation and immunity by chemokine sequestration: Decoys and more. Nat Rev Immunol 6, 907–918 (2006). https://doi.org/10.1038/nri1964 CrossRefPubMed

14.

D. Mukherjee, J. Zhao, The role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res 3, 46–57 (2013)PubMedPubMedCentral

15.

A. Muller, B. Homey, H. Soto, N. Ge, D. Catron, M.E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, S.N. Wagner, J.L. Barrera, A. Mohar, E. Verastegui, A. Zlotnik, Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50–56 (2001). https://doi.org/10.1038/35065016 CrossRefPubMed

16.

B.Z. Qian, J. Li, H. Zhang, T. Kitamura, J. Zhang, L.R. Campion, E.A. Kaiser, L.A. Snyder, J.W. Pollard, CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222–225 (2011). https://doi.org/10.1038/nature10138 CrossRefPubMedPubMedCentral

17.

B. Sharma, K.C. Nannuru, M.L. Varney, R.K. Singh, Host Cxcr2-dependent regulation of mammary tumor growth and metastasis. Clin Exp Metastasis 32, 65–72 (2015). https://doi.org/10.1007/s10585-014-9691-0 CrossRefPubMed

18.

M. Oppermann, Chemokine receptor CCR5: Insights into structure, function, and regulation. Cell Signal 16, 1201–1210 (2004). https://doi.org/10.1016/j.cellsig.2004.04.007 CrossRefPubMed

19.

P. Weitzenfeld, A. Ben-Baruch, The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett 352, 36–53 (2014). https://doi.org/10.1016/j.canlet.2013.10.006 CrossRefPubMed

20.

M. Velasco-Velazquez, R.G. Pestell, The CCL5/CCR5 axis promotes metastasis in basal breast cancer. Oncoimmunology 2, e23660 (2013). https://doi.org/10.4161/onci.23660 CrossRefPubMedPubMedCentral

21.

T.T. Murooka, R. Rahbar, E.N. Fish, CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation. Biochem Biophys Res Commun 387, 381–386 (2009). https://doi.org/10.1016/j.bbrc.2009.07.035 CrossRefPubMed

22.

S. Ali, G. Lazennec, Chemokines: Novel targets for breast cancer metastasis. Cancer Metastasis Rev 26, 401–420 (2007). https://doi.org/10.1007/s10555-007-9073-z CrossRefPubMedPubMedCentral

23.

Y. Niwa, H. Akamatsu, H. Niwa, H. Sumi, Y. Ozaki, A. Abe, Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7, 285–289 (2001)PubMed

24.

S. Sasaki, T. Baba, T. Nishimura, Y. Hayakawa, S. Hashimoto, N. Gotoh, N. Mukaida, Essential roles of the interaction between cancer cell-derived chemokine, CCL4, and intra-bone CCR5-expressing fibroblasts in breast cancer bone metastasis. Cancer Lett 378, 23–32 (2016). https://doi.org/10.1016/j.canlet.2016.05.005 CrossRefPubMed

25.

Y. Zhang, F.Y. Meng, W.L. Li, C.X. Zhou, Z. Guan, H.Y. Fan, Association of chemotactic factor receptor 5 gene with breast cancer. Genet Mol Res 12, 5289–5300 (2013). https://doi.org/10.4238/2013.November.7.4 CrossRefPubMed

26.

A. Khalid, J. Wolfram, I. Ferrari, C. Mu, J. Mai, Z. Yang, Y. Zhao, M. Ferrari, X. Ma, H. Shen, Recent advances in discovering the role of CCL5 in metastatic breast Cancer. Mini Rev Med Chem 15, 1063–1072 (2015)CrossRefPubMedPubMedCentral

27.

A. Pervaiz, M. Zepp, H. Adwan, M.R. Berger, Riproximin modulates multiple signaling cascades leading to cytostatic and apoptotic effects in human breast cancer cells. J Cancer Res Clin Oncol 142, 135–147 (2016). https://doi.org/10.1007/s00432-015-2013-3 CrossRefPubMed

28.

A. Pervaiz, S. Ansari, M.R. Berger, H. Adwan, CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells. Med Oncol 32(158), 158 (2015). https://doi.org/10.1007/s12032-015-0607-x CrossRefPubMed

29.

T. Bauerle, J. Peterschmitt, H. Hilbig, F. Kiessling, F.P. Armbruster, M.R. Berger, Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein. Int J Oncol 28, 573–583 (2006)PubMed

30.

M. Zepp, Bäuerle, T.J., Elazar, V., Peterschmidt, J., Lifshitz-Shovali, R., Adwan, H., Armbruster, F.P., Golomb, G., Berger, M.R., in Breast Cancer, Current and Alternative Therapeutic Modalities, ed. by Gunduz M, Gunduz E. (InTech, Rijeka, 2011), p. 453–488

31.

T. Bauerle, H. Adwan, F. Kiessling, H. Hilbig, F.P. Armbruster, M.R. Berger, Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer 115, 177–186 (2005). https://doi.org/10.1002/ijc.20840 CrossRefPubMed

32.

S. Khokher, M.U. Qureshi, S. Mahmood, S. Sadiq, Determinants of advanced stage at initial diagnosis of breast Cancer in Pakistan: Adverse tumor biology vs delay in diagnosis. Asian Pac J Cancer Prev 17, 759–765 (2016)CrossRefPubMed

33.

M.I. Palacios-Arreola, K.E. Nava-Castro, J.I. Castro, E. Garcia-Zepeda, J.C. Carrero, J. Morales-Montor, The role of chemokines in breast cancer pathology and its possible use as therapeutic targets. J Immunol Res 2014, 849720 (2014). https://doi.org/10.1155/2014/849720 CrossRefPubMedPubMedCentral

34.

T. Kitamura, J.W. Pollard, Therapeutic potential of chemokine signal inhibition for metastatic breast cancer. Pharmacol Res 100, 266–270 (2015). https://doi.org/10.1016/j.phrs.2015.08.004 CrossRefPubMedPubMedCentral

35.

M. Velasco-Velazquez, W. Xolalpa, R.G. Pestell, The potential to target CCL5/CCR5 in breast cancer. Expert Opin Ther Targets 18, 1265–1275 (2014). https://doi.org/10.1517/14728222.2014.949238 CrossRefPubMed

36.

M. Velasco-Velazquez, X. Jiao, M. De La Fuente, T.G. Pestell, A. Ertel, M.P. Lisanti, R.G. Pestell, CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 72, 3839–3850 (2012). https://doi.org/10.1158/0008-5472.CAN-11-3917 CrossRefPubMed

37.

A. Mencarelli, L. Graziosi, B. Renga, S. Cipriani, C. D'Amore, D. Francisci, A. Bruno, F. Baldelli, A. Donini, S. Fiorucci, CCR5 antagonism by Maraviroc reduces the potential for gastric Cancer cell dissemination. Transl Oncol 6, 784–793 (2013)CrossRefPubMedPubMedCentral

38.

Y. Tanabe, S. Sasaki, N. Mukaida, T. Baba, Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation. Oncotarget 7, 48335–48345 (2016). https://doi.org/10.18632/oncotarget.10227 CrossRefPubMedPubMedCentral

39.

N. Halama, I. Zoernig, A. Berthel, C. Kahlert, F. Klupp, M. Suarez-Carmona, T. Suetterlin, K. Brand, J. Krauss, F. Lasitschka, T. Lerchl, C. Luckner-Minden, A. Ulrich, M. Koch, J. Weitz, M. Schneider, M.W. Buechler, L. Zitvogel, T. Herrmann, A. Benner, C. Kunz, S. Luecke, C. Springfeld, N. Grabe, C.S. Falk, D. Jaeger, Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in Cancer patients. Cancer Cell 29, 587–601 (2016). https://doi.org/10.1016/j.ccell.2016.03.005

40.

R. Yost, T.R. Pasquale, E.G. Sahloff, Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection. Am J Health Syst Pharm 66, 715–726 (2009). https://doi.org/10.2146/ajhp080206 CrossRefPubMed

41.

D.K. Walker, S. Abel, P. Comby, G.J. Muirhead, A.N. Nedderman, D.A. Smith, Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 33, 587–595 (2005). https://doi.org/10.1124/dmd.104.002626 CrossRefPubMed

42.

Y. Wu, A. Yoder, Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog 5, e1000520 (2009). https://doi.org/10.1371/journal.ppat.1000520 CrossRefPubMedPubMedCentral

43.

X. Jiao, M.A. Velasco-Velazquez, M. Wang, Z. Li, H. Rui, A.R. Peck, J.E. Korkola, X. Chen, S. Xu, J.B. DuHadaway, S. Guerrero-Rodriguez, S. Addya, D. Sicoli, Z. Mu, G. Zhang, A. Stucky, X. Zhang, M. Cristofanilli, A. Fatatis, J.W. Gray, J.F. Zhong, G.C. Prendergast, R.G. Pestell, CCR5 governs DNA damage and breast cancer stem cell expansion. Cancer Res 78, 1657–1671 (2018). https://doi.org/10.1158/0008-5472.CAN-17-0915 CrossRefPubMedPubMedCentral

44.

S.F. Doisneau-Sixou, C.M. Sergio, J.S. Carroll, R. Hui, E.A. Musgrove, R.L. Sutherland, Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10, 179–186 (2003)CrossRefPubMed

45.

J. Chen, The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med 6, a026104 (2016). https://doi.org/10.1101/cshperspect.a026104 CrossRefPubMedPubMedCentral

46.

S. Manes, E. Mira, R. Colomer, S. Montero, L.M. Real, C. Gomez-Mouton, S. Jimenez-Baranda, A. Garzon, R.A. Lacalle, K. Harshman, A. Ruiz, A.C. Martinez, CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 198, 1381–1389 (2003). https://doi.org/10.1084/jem.20030580 CrossRefPubMedPubMedCentral

47.

X.F. Dai, H.Y. Cheng, Z.H. Bai, J. Li, Breast Cancer cell line classification and its relevance with breast tumor subtyping. J Cancer 8, 3131–3141 (2017). https://doi.org/10.7150/jca.18457 CrossRefPubMedPubMedCentral

48.

D. Gao, R. Rahbar, E.N. Fish, CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells. Open Biol 6 (2016). https://doi.org/10.1098/rsob.160122

49.

D. Gao, L.H. Cazares, E.N. Fish, CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis. BMC Cancer 17, 834 (2017). https://doi.org/10.1186/s12885-017-3817-0

50.

M.J. Sax, C. Gasch, V.R. Athota, R. Freeman, P. Rasighaemi, D.E. Westcott, C.J. Day, I. Nikolic, B. Elsworth, M. Wei, K. Rogers, A. Swarbrick, V. Mittal, N. Pouliot, A.S. Mellick, Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer. Oncotarget 7, 85437–85449 (2016). https://doi.org/10.18632/oncotarget.13387 CrossRefPubMedPubMedCentral

51.

C.E. de Oliveira, J.M. Oda, R. Losi Guembarovski, K.B. de Oliveira, C.B. Ariza, J.S. Neto, B.K. Banin Hirata, M.A. Watanabe, CC chemokine receptor 5: The interface of host immunity and cancer. Dis Markers 126954, 2014–2018 (2014). https://doi.org/10.1155/2014/126954 CrossRef

52.

I. Vasiliadou, I. Holen, The role of macrophages in bone metastasis. J Bone Oncol 2, 158–166 (2013). https://doi.org/10.1016/j.jbo.2013.07.002 CrossRefPubMedPubMedCentral

53.

E. Obeid, R. Nanda, Y.X. Fu, O.I. Olopade, The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol 43, 5–12 (2013). https://doi.org/10.3892/ijo.2013.1938 CrossRefPubMedPubMedCentral

54.

Q. Zhang, J. Qin, L. Zhong, L. Gong, B. Zhang, Y. Zhang, W.Q. Gao, CCL5-mediated Th2 immune polarization promotes metastasis in luminal breast Cancer. Cancer Res 75, 4312–4321 (2015). https://doi.org/10.1158/0008-5472.CAN-14-3590 CrossRefPubMed

55.

Y. Vahidi, Z. Faghih, A.R. Talei, M. Doroudchi, A. Ghaderi, Memory CD4(+) T cell subsets in tumor draining lymph nodes of breast cancer patients: A focus on T stem cell memory cells. Cell Oncol 41, 1–11 (2018). https://doi.org/10.1007/s13402-017-0352-6 CrossRef

56.

I.A. Voutsadakis, Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: Therapeutic implications. Cell Oncol 41, 107–121 (2018). https://doi.org/10.1007/s13402-018-0373-9 CrossRef

57.

E. Lee, E.J. Fertig, K. Jin, S. Sukumar, N.B. Pandey, A.S. Popel, Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nat Commun 5, 4715 (2014). https://doi.org/10.1038/ncomms5715

Title: CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer
Authors: Asim Pervaiz
Michael Zepp
Saqib Mahmood
Doaa Mohamed Ali
Martin R. Berger
Hassan Adwan
Publication date: 01-02-2019
Publisher: Springer Netherlands
Published in: Cellular Oncology / Issue 1/2019
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-018-0415-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

SOX3 can promote the malignant behavior of glioblastoma cells

Molecular features unique to glioblastoma radiation resistant residual cells may affect patient outcome - a short report

Radio-sensitization of head and neck cancer cells by a combination of poly(I:C) and cisplatin through downregulation of survivin and c-IAP2

Cell-free DNA in cancer: current insights

Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death

CCL18 secreted from M2 macrophages promotes migration and invasion via the PI3K/Akt pathway in gallbladder cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer